GANX.US Gain Therapeutics Inc

Healthcare Biotechnology USA Stocks
1.04 USD
Close of Nov 14, 2026
0.9402 4.34
Market cap
USD 46.3M
P/E
-
P/B
4.26x
ROE
-176.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is GANX.US undervalued?

Graham number

The Graham number of Gain Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Gain Therapeutics Inc fundamental analysis

No fundamental analysis for Gain Therapeutics Inc yet.

Gain Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Gain Therapeutics Inc

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, …

Full company profile